TIDMYGEN
RNS Number : 2804J
Yourgene Health PLC
26 April 2022
Yourgene Health plc
("Yourgene", "Group", or the "Company")
Directorate Change
Manchester, UK - 26 April 2022: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, announces that after a
five-year tenure, Adam Reynolds will step down from his position as
Chairman, at the Company's next Annual General Meeting ("AGM"). The
Board is pleased to confirm that he will remain on the Board as a
Non-executive Director.
Dr John Brown CBE, currently a Non-executive Director of the
Company and its Senior Independent Director, will assume the role
of Chairman of the Group from the same date.
Adam Reynolds has been instrumental in transforming the Company
in his five years of service as Chairman, and before that as a
Non-executive Director, overseeing key hires on the senior
leadership team, rebuilding and navigating the Company post
litigation and guiding Yourgene through several successful
acquisitions, all contributing to the Group recording record
revenue growth, sustaining a step change in financial performance
and creating a broader offering of products and services. In the
coming months Adam will ensure an orderly handover and transition
to a Non-executive Director role.
Dr John Brown joined the Board of Yourgene on 29 July 2019 as a
Non-executive Director and has acted as Senior Independent Director
to the Company. Dr Brown has over 20 years' capital markets
experience in the healthcare and life sciences sector. He is
currently a Senior Independent Director of Acacia Pharma and is
Chairman of Calcivis. Additionally, he has previous significant
board experience with roles including Chairman of Axis-Shield, BTG
and Cell Therapy Catapult, Non-executive Director of Vectura and
Chief Executive Officer of Acambis.
Adam Reynolds, outgoing Chairman of Yourgene, said: "As we
embark on the next phase of Yourgene's journey we have a very
strong successor in Dr John Brown as Chairman. I will remain on the
Board as a supportive NED and shareholder and I remain as convinced
as ever in the prospects for Yourgene Health."
Lyn Rees, CEO of Yourgene, said: "I would like to thank Adam for
his support and contribution to Yourgene, as the Group has
transformed into the business it is today. Adam has been
instrumental in overseeing the growth we have achieved and we are
pleased that we can retain his extensive experience and knowledge
as he remains a supportive NED.
"We are thrilled Dr John Brown is becoming the Group's Chairman,
a testament to Yourgene attracting such a high calibre and
experienced Chair, who has been able to get to know the business
over the last couple of years whilst in his current NED role. The
breadth of capital markets experience in the healthcare sector Dr
Brown can offer Yourgene is paramount as the Group enters its next
stage of growth and development."
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this
announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000
Broker)
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / Mob: 07584 391
/ Alice Woodings 303 /
Mob: 07407 804 654
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics , Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAZZGZDLKZGZZM
(END) Dow Jones Newswires
April 26, 2022 10:06 ET (14:06 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
